Implementing Virtual Reality Exposure Therapy for Vaginismus: From Efficacy to Clinical Integration (VIVID 3)

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age19+
SponsorUniversity of British Columbia

About this trial

Vaginismus, a condition characterized by involuntary tightening of the pelvic floor muscles due to strong fear of vaginal insertion, impact ≥6% of the female population and can make vaginal intercourse and medical exams difficult. This project explores virtual reality exposure (VRE) as a new treatment approach. Building on our two previous studies showing that VRE is feasible and effective in helping patients to gradually face feared sexual encounters in a virtual environment, we aim to implement our VRE protocol at the BC Centre for Vulvar Health (BCCVH). We will assess barriers/facilitators to implementation, clinician uptake, and patients' outcomes and engagement.

Eligibility criteria

Qualifiers

Diagnosis of vaginismus defined by a "marked fear or anxiety about vulvovaginal or pelvic pain in anticipation of, during, or because of vaginal penetration" (criterion from the DSM-5 definition of Genito-Pelvic Pain Penetration Disorder)

Aged >19 y, of any sexual orientation

Fluent in English (psychoeducational materials and questionnaires delivered in English)

Normal or corrected-to-normal vision (to view the VR scenes during exposure)

Disqualifiers

Presence of: unprovoked vaginal pain

Vulvar skin condition (i.e., lichen sclerosus)

Epilepsy characterized by photosensitive seizures.

Trial design

Treatments tested in this trial

  • Implementation of Virtual Reality Exposure

Treatment groups

167 Participants
are divided into 1 treatment group

Sponsors and collaborators